These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33257603)

  • 21. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19: benefits and risks of passive immunotherapeutics.
    Gupta A; Karki R; Dandu HR; Dhama K; Bhatt ML; Saxena SK
    Hum Vaccin Immunother; 2020 Dec; 16(12):2963-2972. PubMed ID: 32962524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome.
    Diorio C; Anderson EM; McNerney KO; Goodwin EC; Chase JC; Bolton MJ; Arevalo CP; Weirick ME; Gouma S; Vella LA; Henrickson SE; Chiotos K; Fitzgerald JC; Kilbaugh TJ; John ARO; Blatz AM; Lambert MP; Sullivan KE; Tartaglione MR; Zambrano D; Martin M; Lee JH; Young P; Friedman D; Sesok-Pizzini DA; Hensley SE; Behrens EM; Bassiri H; Teachey DT
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28693. PubMed ID: 32885904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
    Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
    Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-Dose Convalescent Plasma for Treatment of Severe COVID-19 (response).
    De Santis GC; Calado RT
    Emerg Infect Dis; 2022 May; 28(5):1083-1084. PubMed ID: 35447061
    [No Abstract]   [Full Text] [Related]  

  • 26. Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy.
    Casadevall A; Joyner MJ; Pirofski LA
    Clin Infect Dis; 2021 Aug; 73(3):e540-e542. PubMed ID: 32805024
    [No Abstract]   [Full Text] [Related]  

  • 27. Successful recovery of COVID-19-associated recurrent diarrhea and gastrointestinal hemorrhage using convalescent plasma.
    Zhang LB; Pang RR; Qiao QH; Wang ZH; Xia XY; Wang CJ; Xu XL
    Mil Med Res; 2020 Sep; 7(1):45. PubMed ID: 32962760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma.
    Gemici A; Bilgen H; Erdoğan C; Kansu A; Olmuşçelik O; Beköz HS; Çakmak R; Mert A; Sevindik ÖG
    Turk J Med Sci; 2020 Dec; 50(8):1781-1785. PubMed ID: 33078604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Convalescent plasma for COVID-19 considerations.
    Adiwinata Pawitan J
    Transfus Apher Sci; 2021 Feb; 60(1):102927. PubMed ID: 32878733
    [No Abstract]   [Full Text] [Related]  

  • 30. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma.
    Kong Y; Cai C; Ling L; Zeng L; Wu M; Wu Y; Zhang W; Liu Z
    Transfus Apher Sci; 2020 Oct; 59(5):102820. PubMed ID: 32467007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer.
    Bloch EM; Crowe EP; Tobian AAR
    J Infect Dis; 2021 Mar; 223(5):740-742. PubMed ID: 33411937
    [No Abstract]   [Full Text] [Related]  

  • 33. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of convalescent plasma in COVID-19 patients with immunosuppression.
    Senefeld JW; Klassen SA; Ford SK; Senese KA; Wiggins CC; Bostrom BC; Thompson MA; Baker SE; Nicholson WT; Johnson PW; Carter RE; Henderson JP; Hartman WR; Pirofski LA; Wright RS; Fairweather L; Bruno KA; Paneth NS; Casadevall A; Joyner MJ
    Transfusion; 2021 Aug; 61(8):2503-2511. PubMed ID: 34036587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-Dose Convalescent Plasma for Treatment of Severe COVID-19.
    Focosi D; Casadevall A
    Emerg Infect Dis; 2022 May; 28(5):1083. PubMed ID: 35450567
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis.
    Vegivinti CTR; Pederson JM; Saravu K; Gupta N; Evanson KW; Kamrowski S; Schmidt M; Barrett A; Trent H; Dibas M; Reierson NL; Mikoff N; Pisipati S; Joseph BA; Selvan PT; Dmytriw AA; Pulakurthi YS; Keesari PR; Sriram V; Chittajallu S; Brinjikji W; Katamreddy RR; Chibbar R; Davis AR; Malpe M; Mishra HK; Kallmes KM; Hassan AE
    J Clin Apher; 2021 Jun; 36(3):470-482. PubMed ID: 33544910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
    Pavia CS; Wormser GP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.
    Senefeld JW; Johnson PW; Kunze KL; Bloch EM; van Helmond N; Golafshar MA; Klassen SA; Klompas AM; Sexton MA; Diaz Soto JC; Grossman BJ; Tobian AAR; Goel R; Wiggins CC; Bruno KA; van Buskirk CM; Stubbs JR; Winters JL; Casadevall A; Paneth NS; Shaz BH; Petersen MM; Sachais BS; Buras MR; Wieczorek MA; Russoniello B; Dumont LJ; Baker SE; Vassallo RR; Shepherd JRA; Young PP; Verdun NC; Marks P; Haley NR; Rea RF; Katz L; Herasevich V; Waxman DA; Whelan ER; Bergman A; Clayburn AJ; Grabowski MK; Larson KF; Ripoll JG; Andersen KJ; Vogt MNP; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Buchholtz ZA; Pletsch MC; Wright K; Greenshields JT; Joyner MJ; Wright RS; Carter RE; Fairweather D
    PLoS Med; 2021 Dec; 18(12):e1003872. PubMed ID: 34928960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-19 convalescent plasma therapy and immunodeficiency.
    Mungmunpuntipantip R; Wiwanitkit V
    Transfus Clin Biol; 2021 Aug; 28(3):306-307. PubMed ID: 34116917
    [No Abstract]   [Full Text] [Related]  

  • 40. [Convalescent plasma therapy in COVID-19 patients].
    Ascencios L; Casa L
    Medicina (B Aires); 2021; 81(2):306. PubMed ID: 33906156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.